Nelson Syndrome: A Rare Cause of Generalized Hyperpigmentation of the Skin

Barabash, R.; Moreno-Suárez, F.G.; Rodríguez, L.; Molina, A.M.; Conejo-Mir, J.

doi:10.1016/S1578-2190(10)70582-5

Información del artículo

Resumen

Bibliografía

Descargar PDF

Estadísticas

Abstract

Nelson syndrome is a rare cause of generalized mucocutaneous hyperpigmentation. Its clinical manifestations are due to excessive secretion of adrenocorticotropic hormone from a pituitary adenoma, which develops after bilateral therapeutic adrenalectomy. As this operation has fallen into disuse, Nelson syndrome is now extremely rare and difficult to recognize. We present a very severe case of generalized hyperpigmentation due to Nelson syndrome in a 37-year-old woman.

Keywords:

Nelson syndrome

Hyperpigmentation

Adrenalectomy

Resumen

El síndrome de Nelson (SN) supone una causa infrecuente de hiperpigmentación mucocutánea generalizada, cuyas manifestaciones clínicas se derivan de la secreción excesiva de corticotropina por un adenoma hipofisario secundario a la realización de una suprarrenalectomía bilateral terapéutica. Debido a que esta intervención quirúrgica ha caído en desuso en la actualidad, su presentación es hoy sumamente rara y poco reconocible. Presentamos un caso muy grave de hiperpigmentación generalizada por SN en una paciente de 37 años.

Palabras clave:

Síndrome de Nelson

Hiperpigmentación

Suprarrenalectomía

El Texto completo está disponible en PDF

References

[1.]

D.H. Nelson, J.W. Meakin, J.B. Dealy, D.D. Matson, K. Emerson, G.W. Thorn.

ACTH-producing tumor of the pituitary gland.

N Engl J Med, 259 (1958), pp. 161-164

http://dx.doi.org/10.1056/NEJM195807242590403 | Medline

[2.]

M. Hornyak, M.H. Weiss, D.H. Nelson, W.T. Couldwell.

Nelson syndrome: Historical perspectives and current concepts.

Neurosurg Focus, 23 (2007), pp. E12

http://dx.doi.org/10.3171/FOC-07/12/E12 | Medline

[3.]

S.K. Nagesser, A.P. Van Seters, J. Kievit, J. Hermans, H.M. Krans, C.J. Van de Velde.

Long-term results of total adrenalectomy for Cushing's disease.

World J Surg, 24 (2000), pp. 108-113

Medline

[4.]

M.O. Van Aken, A.M. Pereira, G. Van den Berg, J.A. Romijn, J.D. Veldhuis, F. Roelfsema.

Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.

Clin Endocrinol (Oxf), 60 (2004), pp. 765-772

[5.]

Y. Chapuis, J. Pitre, F. Conti, B. Abboud, N. Pras-Jude, J.P. Luton.

Role and operative risk of bilateral adrenalectomy in hypercortisolism.

World J Surg, 20 (1996), pp. 775-780

Medline

[6.]

C. Tsigos, D.A. Papanicolaou, G.P. Chrousos.

Advances in the diagnosis and treatment of Cushing's syndrome.

Baillieres Clin Endocrinol Metab, 9 (1995), pp. 315-336

Medline

[7.]

P.A. Kelly, G. Samandouras, A.B. Grossman, F. Afshar, G.M. Besser, P.J. Jenkins.

Neurosurgical treatment of Nelson's syndrome.

J Clin Endocrinol Metab, 87 (2002), pp. 5465-5469

http://dx.doi.org/10.1210/jc.2002-020299 | Medline

[8.]

A. Gil-Cárdenas, M.F. Herrera, A. Díaz-Polanco, J.M. Ríos, J.P. Pantoja.

Nelson's syndrome after bilateral adrenalectomy for Cushing's disease.

Surgery, 141 (2007), pp. 147-152

http://dx.doi.org/10.1016/j.surg.2006.12.003 | Medline

[9.]

R.E. Mains, B.A. Eipper, N. Ling.

Common precursor to corticotropins and endorphins.

Proc Natl Acad Sci USA, 74 (1977), pp. 3014-3018

Medline

[10.]

M.A. Pereira, A. Halpern, L.R. Salgado, B.B. Mendonça, M. Nery, B. Liberman, et al.

A study of patients with Nelson's syndrome.

Clin Endocrinol (Oxf), 49 (1998), pp. 533-539

[11.]

C. Höybye, E. Grenbäck, T. Rähn, M. Degerblad, M. Thorén, A.L. Hulting.

Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.

Neurosurgery, 49 (2001), pp. 284-292

Medline

[12.]

M. Buchfelder, R. Nistor, R. Fahlbusch, W.J. Huk.

The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease.

Am J Neuroradiol, 14 (1993), pp. 1183-1190

Medline

[13.]

J. Estrada, M. Boronat, M. Mielgo, R. Magallón, I. Millan, S. Díez, et al.

The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

N Engl J Med, 336 (1997), pp. 172-177

http://dx.doi.org/10.1056/NEJM199701163360303 | Medline

[14.]

A.A. Kasperlik-Zaluska, W. Zgliczynski, W. Jeske, P. Zdunowski.

ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome.

Neuro Endocrinol Lett, 26 (2005), pp. 709-712

Medline

[15.]

F. Kelestimur, C. Utas, O. Ozbakir, A. Selcuklu, O. Kandemir, N. Ozcan.

The effects of octreotide in a patient with Nelson's syndrome.

Postgrad Med J, 72 (1996), pp. 53-54

Medline

[16.]

A.A. Kasperlik-Zaluska, W. Bonicki, W. Jeske, J. Janik, W. Zgliczynski, Z. Czernicki.

Nelson's syndrome—46 years later: Clinical experience with 37 patients.

Zentralbl Neurochir, 67 (2006), pp. 14-20

http://dx.doi.org/10.1055/s-2006-921430 | Medline

[17.]

G. Assié, H. Bahurel, J. Coste, S. Silvera, M. Kujas, M.A. Dugué, et al.

Corticotroph tumor progression after adrenalectomy in Cushing's disease: A reappraisal of Nelson's syndrome.

J Clin Endocrinol Metab, 92 (2007), pp. 172-179

http://dx.doi.org/10.1210/jc.2006-1328 | Medline

[18.]

K.U. Schallreuter, M.R. Pittelkow, J.M. Wood.

Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells.

J Invest Dermatol, 88 (1987), pp. 516

[19.]

M. Nazzaro-Porro, S. Passi, G. Zina, A.S. Breathnach.

Ten years’ experience of treating lentigo maligna with topical azelaic acid.

Acta Derm Venereol (Stockh), 143 (1989), pp. 49-57

[20.]

H. Leibl, G. Stingl, H. Pehamberger, H. Korschan, K. Konrad, K. Wolff.

Inhibition of DNA synthesis of melanoma cells by azelaic acid.

J Invest Dermatol, 85 (1985), pp. 417-422

Medline

Indexada en:

Síguenos:

Indexada en:

Síguenos:

Suscríbase a la newsletter